---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-25-000128"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T01:47:54.198288+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Denali Therapeutics elects Julian Baker as director; grants registration rights to Baker Brothers funds

## Summary
- Julian C. Baker elected as Class II director; 98.0M votes for, 22.9M withheld.
- Registration rights agreement with BBA Funds grants resale registration rights; company must file S-3 within 60 days of request.
- Ratified Ernst & Young as independent auditor for FY2025; advisory say-on-pay approved with 90.2% of shares represented.

## SEC filing metadata
- accession: 0001714899-25-000128
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489925000128/0001714899-25-000128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489925000128/dnli-20250603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-25-000128
- JSON: https://secwatch.observer/filing/0001714899-25-000128.json
- Plain text: https://secwatch.observer/filing/0001714899-25-000128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.